Pharma BD Deal Intelligence
Filgotinib's Phase 2 RA data drove the Gilead partnership, though a single DVT case foreshadowed the JAK class-wide thrombosis safety concerns that would…
Gilead returned filgotinib rights to Galapagos in late 2020, marking a clear failure of the 2015 collaboration's US thesis and a setback for CEO O'Day's…
Filgotinib received first approval in Japan/EU as Jyseleca for RA in 2020, validating the JAK1-selective mechanism in ex-US markets despite the FDA setback.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Gilead and Galapagos closed their global license and collaboration for filgotinib, a selective JAK1 inhibitor in Phase 3 for rheumatoid arthritis. Galapagos received $725M upfront ($300M license fee + $425M equity investment giving Gilead 14.75% stake at EUR58/share). Galapagos eligible for up to $1.35B in milestones plus tiered royalties starting at 20%, with co-promotion profit splits in select territories.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / Galapagos NV (this deal) | 2016 | $2.1B | 19 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Immunomedics Inc. | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
← Browse all deals · How we score deals
More: 2016 deals · Gilead Sciences Inc. deals · Gastroenterology deals